Why did GAAP EPS rise so much more than revenue?

GAAP diluted EPS of $3.52 was up 45.5% on revenue growth of 8.7%. Gross profit rose 20.6%, helped by a $52.1M LIFO credit versus a $6.8M LIFO expense a year earlier. Diluted share count fell 2.4% on buybacks. Other income of about $110M, including equity-investment gains and a Swiss tax remeasurement gain, also lifted GAAP results, and these items are excluded from adjusted EPS.

What is driving growth in the U.S. Healthcare Solutions segment?

Growth came mainly from unit volume, including higher sales of GLP-1 class products for diabetes and weight loss and specialty products sold to physician practices and health systems. The January 2025 acquisition of Retina Consultants of America also contributed to higher gross profit and operating expenses.

Why is International Healthcare Solutions profit falling even though revenue is growing?

International revenue rose 10.5%, but segment operating income fell 12.9%, primarily due to lower operating income at the global specialty logistics business and the specialized consulting services business. On a constant-currency basis, operating income declined 16.2%. Management now expects the full-year International operating income decline to be about 6%.

How has the balance sheet changed, and does it raise concerns?

Long-term debt rose to about $8.0B at June 30, 2025, from $3.8B at September 30, 2024, mainly to finance the RCA acquisition. Quarterly net interest expense rose to $81.8M from $31.3M. Nine-month operating cash flow fell to $741.7M from $2.48B, and adjusted free cash flow was only $92.5M. Investors should watch whether cash generation catches up with the higher debt load.

What should investors know about the non-GAAP figures?

Adjusted results exclude acquisition amortization, deal and integration costs, restructuring, opioid and litigation expenses, LIFO and Turkey inflation effects, antitrust settlement gains, and certain tax and investment gains. Management argues these items are unusual or non-cash. The adjusted adjustments removed about $0.9 in quarterly GAAP-to-adjusted EPS, so the GAAP figures should be reviewed alongside adjusted numbers.

COR 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.

Cencora (COR) reported fiscal Q3 2025 (quarter ended June 30, 2025) with revenue of $80.7 billion^a, up 8.7% year-over-year, driven by 8.5% growth in U.S. Healthcare Solutions and 10.5% growth in International Healthcare Solutions.

GAAP diluted EPS was $3.52^b (up 45.5%), while adjusted diluted EPS, a non-GAAP measure, rose 19.8% to $4.00. Adjusted operating income grew 20.6% to $1.1 billion, with the U.S. segment (up 29.1% in operating income, boosted by GLP-1 product volume and the January 2025 acquisition of Retina Consultants of America) doing most of the work. International operating income fell 12.9%, pulled down by the global specialty logistics and specialized consulting businesses.

Management raised its fiscal 2025 adjusted diluted EPS guidance to $15.85^c–$16.00 from $15.70–$15.95, citing stronger U.S. Healthcare Solutions earnings. Adjusted operating income growth guidance moved up to 15–16%, and U.S. segment operating income growth is now expected at 20–21%. The International segment outlook was mixed: revenue growth was raised to 6–7%, but operating income is now expected to decline about 6%, a weaker view than before.

Investors should also note the balance-sheet shift from the RCA acquisition: long-term debt rose to about $8.0 billion^d from $3.8 billion at September 30, 2024, and interest expense, net, more than doubled from the prior-year quarter. Nine-month adjusted free cash flow was only $92.5 million, and GAAP operating cash flow fell to $741.7 million from $2.48 billion a year earlier, largely because of working capital changes. The company also declared a quarterly dividend of $0.55 per share, payable September 3, 2025, to holders of record on August 15, 2025.

This filing is a furnished (not filed) 8-K that attaches the earnings press release and points to the conference call on August 6, 2025 at 8:30 a.m. ET.

02—Key points

Key Highlights

Q3 FY2025 revenue of $80.7B, up 8.7% YoY; U.S. Healthcare Solutions up 8.5% and International up 10.5%
GAAP diluted EPS of $3.52 (up 45.5% YoY); adjusted diluted EPS of $4.00 (up 19.8% YoY)
Adjusted diluted EPS guidance for FY2025 raised to $15.85–$16.00 from $15.70–$15.95
U.S. Healthcare Solutions segment operating income up 29.1% to $901.8M, driven by GLP-1 volume and the RCA acquisition
International Healthcare Solutions operating income fell 12.9% to $156.2M; FY2025 operating income decline now expected at about 6%
Gross margin rose to 3.60% (GAAP) from 3.25%, helped by a $52.1M LIFO credit, partly offset by lower antitrust settlement gains
Quarterly dividend of $0.55 per share declared, payable September 3, 2025 (record date August 15, 2025)

03—Questions

Frequently Asked Questions

Why did GAAP EPS rise so much more than revenue?
GAAP diluted EPS of $3.52 was up 45.5% on revenue growth of 8.7%. Gross profit rose 20.6%, helped by a $52.1M LIFO credit versus a $6.8M LIFO expense a year earlier. Diluted share count fell 2.4% on buybacks. Other income of about $110M, including equity-investment gains and a Swiss tax remeasurement gain, also lifted GAAP results, and these items are excluded from adjusted EPS.
What is driving growth in the U.S. Healthcare Solutions segment?
Growth came mainly from unit volume, including higher sales of GLP-1 class products for diabetes and weight loss and specialty products sold to physician practices and health systems. The January 2025 acquisition of Retina Consultants of America also contributed to higher gross profit and operating expenses.
Why is International Healthcare Solutions profit falling even though revenue is growing?
International revenue rose 10.5%, but segment operating income fell 12.9%, primarily due to lower operating income at the global specialty logistics business and the specialized consulting services business. On a constant-currency basis, operating income declined 16.2%. Management now expects the full-year International operating income decline to be about 6%.
How has the balance sheet changed, and does it raise concerns?
Long-term debt rose to about $8.0B at June 30, 2025, from $3.8B at September 30, 2024, mainly to finance the RCA acquisition. Quarterly net interest expense rose to $81.8M from $31.3M. Nine-month operating cash flow fell to $741.7M from $2.48B, and adjusted free cash flow was only $92.5M. Investors should watch whether cash generation catches up with the higher debt load.
What should investors know about the non-GAAP figures?
Adjusted results exclude acquisition amortization, deal and integration costs, restructuring, opioid and litigation expenses, LIFO and Turkey inflation effects, antitrust settlement gains, and certain tax and investment gains. Management argues these items are unusual or non-cash. The adjusted adjustments removed about $0.9 in quarterly GAAP-to-adjusted EPS, so the GAAP figures should be reviewed alongside adjusted numbers.

04—Continue

← View all 8-K filings